ライフサイエンスコーパス: antisense oligodeoxynucleotide

1 titutively active form of p38 and by an Mdm2-antisense oligodeoxynucleotide.

2 tinuous 7 d intrastriatal infusion of ERK1/2 antisense oligodeoxynucleotide.

3 nd 90% in lungs treated with Smad3 and Smad2 antisense oligodeoxynucleotide.

4 phine with the GR antagonist RU38486 or a GR antisense oligodeoxynucleotide.

5 the erbB-2 receptor was down-regulated using antisense oligodeoxynucleotides.

6 profiles of the same cells transfected with antisense oligodeoxynucleotides.

7 T(1A) antagonists) was not inhibited by G(z) antisense oligodeoxynucleotides.

8 ession than the widely used phosphorothioate antisense oligodeoxynucleotides.

9 ected into Xenopus oocytes with Apx sense or antisense oligodeoxynucleotides.

10 nopus embryos by blocking its synthesis with antisense oligodeoxynucleotides.

11 odified ASOs as compared to first-generation antisense oligodeoxynucleotides.

12 alpha 3, Gs alpha, Gq alpha, and Gx/z alpha antisense oligodeoxynucleotides.

13 ence, we directly targeted neurogranin using antisense oligodeoxynucleotides.

14 suppression of syndecan-4 core protein with antisense oligodeoxynucleotides.

15 eted carriers, bio-adhesive microspheres and antisense oligodeoxynucleotides.

16 subjective day after administration of CalB antisense oligodeoxynucleotides.

17 ly 25% in rats treated with insulin receptor antisense oligodeoxynucleotides.

18 The intracerebellar pretreatment with antisense oligodeoxynucleotide (3.0 microgram/100 nl/12

19 spectively, in cultured embryonic lungs when antisense oligodeoxynucleotide (40 microM) to Smad was a

20 lation of Mos synthesis by microinjection of antisense oligodeoxynucleotides abolished activation of

21 d paws with an 18-mer 3'-3'-end inverted CRF-antisense oligodeoxynucleotide abolishes CWS-induced ant

22 Knockdown of CREB with antisense oligodeoxynucleotide against CREB reduced mech

23 pha bioactivity) or knockdown of TNFRI using antisense oligodeoxynucleotide against TNFRI reduced mec

24 Antisense oligodeoxynucleotides against bcl-2, c-raf-1,

25 measured while inhibiting CaMKII either with antisense oligodeoxynucleotides against CaMKII or with t

26 Treatment with antisense oligodeoxynucleotides against CaMKII resulted

27 dels of vascular proliferative disease using antisense oligodeoxynucleotides against cell cycle genes

28 P2)/CUL-1 complex, we have used the specific antisense oligodeoxynucleotides against either SKP1, SKP

29 en when adult brain mRNA was coinjected with antisense oligodeoxynucleotides against the NR2A subunit

30 e present study examined the actions of four antisense oligodeoxynucleotides aimed at exons 1 (AS1),

31 cyclase (GC) inhibitors, PKG inhibition, or antisense oligodeoxynucleotide (alphaODN) specific for P

32 m mediator of Smad3 and Smad2 proteins, with antisense oligodeoxynucleotide, also resulted in increas

33 reduced by inhibiting Ngb expression with an antisense oligodeoxynucleotide and enhanced by Ngb overe

34 Demonstrating hybridization between an antisense oligodeoxynucleotide and its mRNA target has p

35 ssing cells was treated with an OVA-specific antisense oligodeoxynucleotide and RNase H, showing that

36 , by dominant-interfering MKK3, and by a p53-antisense oligodeoxynucleotide and was increased by a co

37 apping results facilitated identification of antisense oligodeoxynucleotides and a 10-23 deoxyribozym

38 le inhibitors of the IGF-IR tyrosine kinase, antisense oligodeoxynucleotides and antisense RNA, small

39 bition of PKCmicro synthesis and activity by antisense oligodeoxynucleotides and H-89 (N-(2-[p-bromoc

40 In vitro studies using antisense oligodeoxynucleotides and integrin activation

41 ges of HIPBS and its flanking sequences with antisense oligodeoxynucleotides and RNase H and then by

42 An antisense oligodeoxynucleotide annealing across the Lab

43 or function, we developed a phosphorothioate antisense oligodeoxynucleotide (AO) to inhibit the expre

44 study examined how selective knock-down (via antisense oligodeoxynucleotides, aODNs) of GABA(A) recep

45 Antisense oligodeoxynucleotides (AONs) and short interfe

46 The effects of antisense oligodeoxynucleotide (AS ODN) against NF-kappa

47 opioid receptor-sensitive feeding, different antisense oligodeoxynucleotide (AS ODN) probes directed

48 nists, and through central administration of antisense oligodeoxynucleotide (AS ODN) probes directed

49 Antisense oligodeoxynucleotide (AS ODN) probes directed

50 at ex vivo donor allograft transfection with antisense oligodeoxynucleotide (AS ODN) would inhibit th

51 this response, mice were pretreated with an antisense oligodeoxynucleotide (AS-ODN) against neuronal

52 expression using cisterna magna infusion of antisense oligodeoxynucleotide (AS-ODN).

53 herapy of rabbit autologous vein grafts with antisense oligodeoxynucleotides (AS ODN) blocking cell c

54 Antisense oligodeoxynucleotides (AS ODNs) directed again

55 Antisense oligodeoxynucleotides (AS-ODN) and their modif

56 sure as a vector for ex vivo transfection of antisense oligodeoxynucleotides (AS-ODN) to intercellula

57 The application of antisense oligodeoxynucleotides (AS-ODNs) against these

58 -Dawley rats were treated intravenously with antisense oligodeoxynucleotides (AS-ODNs) directed at AT

59 cts of unilateral microinfusions of GluR2(B) antisense oligodeoxynucleotides (AS-ODNs) into the hippo

60 ect of inhibition of BCR-ABL expression with antisense oligodeoxynucleotides (AS-ODNs) on integrin-me

61 mplicated in some forms of neuropathic pain, antisense oligodeoxynucleotides (AS-ODNs) or mismatch OD

62 n EAAU was explored using neutralizing mAbs, antisense oligodeoxynucleotides (AS-ODNs), and small int

63 pletion of either Galpha(o) or Galpha(q) via antisense oligodeoxynucleotides, as well as by inhibitor

64 resistin levels in mice by use of a specific antisense oligodeoxynucleotide (ASO) directed against re

65 inistration (2 injections over 1 week) of an antisense oligodeoxynucleotide (ASO) directed to reduce

66 characterized the mechanism of action of an antisense oligodeoxynucleotide (ASO) targeting human end

67 ulin resistance, we used a sequence-specific antisense oligodeoxynucleotide (ASO) to lower hepatic Sc

68 The activity of a 20-mer antisense oligodeoxynucleotide (asODN) is transiently bl

69 ing novel phosphorothioate-2'-O-methoxyethyl antisense oligodeoxynucleotides (asODN).

70 ucts of connexin 43 (Cx43) and Cx43-specific antisense oligodeoxynucleotides (asODNs) all act to slow

71 g with pharmacological agents, Cx43-specific antisense oligodeoxynucleotides (asODNs) or dominant neg

72 om P15 atrial myocytes exposed to (1 microM) antisense oligodeoxynucleotides (AsODNs) targeted agains

73 al IK,fast, IK, slow and Iss, the effects of antisense oligodeoxynucleotides (AsODNs) targeted agains

74 Antisense oligodeoxynucleotides (AsODNs) targeted agains

75 Light-activated antisense oligodeoxynucleotides (asODNs) were developed

76 Five different antisense oligodeoxynucleotides based upon the three DOR

77 hesis that down-regulation of Bcl-2 alone by antisense oligodeoxynucleotides (Bcl-2-AS) induces apopt

78 Bcl-2 antisense oligodeoxynucleotides (Bcl-2-ASO) have been sh

79 Spinal administration of TRPV4 antisense oligodeoxynucleotide blocked the enhancement w

80 nsfection of wing and leg cell cultures with antisense oligodeoxynucleotides blocked appearance of ec

81 tificial down-regulation of PKC-epsilon with antisense oligodeoxynucleotides blocked erythropoietin's

82 rc activity associated with gelsolin through antisense oligodeoxynucleotides blocked the stimulation

83 ecreased by 78% after 7 days in culture with antisense oligodeoxynucleotides but was unchanged in tis

84 Plasmids, RNA interference and antisense oligodeoxynucleotides can be readily introduce

85 Antisense oligodeoxynucleotides can selectively block di

86 s, and inclusion of IR beta-subunit-specific antisense oligodeoxynucleotide caused marked dysmorphoge

87 ozygous for Epac1 or mice treated with Epac1 antisense oligodeoxynucleotides, chronic PGE2-induced hy

88 rsal horn after chronic morphine, and a CREB antisense oligodeoxynucleotide coadministered intratheca

89 An antisense oligodeoxynucleotide complementary to IL-1alph

90 An 18-base antisense oligodeoxynucleotide complementary to the cis-

91 Two different 19-mer antisense oligodeoxynucleotides complementary to the ini

92 expression was specifically inhibited by an antisense oligodeoxynucleotide containing two phosphorot

93 MB probes are structured as target-specific antisense oligodeoxynucleotides containing a proximate f

94 Second, effects of antisense oligodeoxynucleotides (D-oligos) for GAD67 and

95 he erbB-2 receptor protein by trastuzumab or antisense oligodeoxynucleotides decreased Akt kinase act

96 inhibition of PKG-II but not PKG-Ibeta using antisense oligodeoxynucleotides delayed rhythms of elect

97 fer several advantages over other methods of antisense oligodeoxynucleotide delivery including effici

98 a-neoendorphin analgesia towards the various antisense oligodeoxynucleotides differed markedly from U

99 Treatment of cultures with an antisense oligodeoxynucleotide directed against bcl-2 mR

100 ays of daily treatment of K562 cells with an antisense oligodeoxynucleotide directed against the init

101 cal animal experiments support the use of an antisense oligodeoxynucleotide directed against the insu

102 We generated an antisense oligodeoxynucleotide directed against the insu

103 namic properties of CGP 69846A/ISIS 5132, an antisense oligodeoxynucleotide directed against the mito

104 Antisense oligodeoxynucleotide directed to mGluR1, but n

105 Antisense oligodeoxynucleotides directed against CFTR si

106 tidylinositol 3-kinase inhibitor LY294002 or antisense oligodeoxynucleotides directed against JAK2, E

107 t of several SCCHN cell lines with a pair of antisense oligodeoxynucleotides directed against the tra

108 udies using both neutralizing antibodies and antisense oligodeoxynucleotides directed against these c

109 Antisense oligodeoxynucleotides directed against various

110 Suppression of gravin expression via antisense oligodeoxynucleotides disrupted agonist-induce

111 rs review the early clinical experience with antisense oligodeoxynucleotides, documenting their limit

112 in the presence of TGF-beta type II receptor antisense oligodeoxynucleotides either alone or together

113 which encodes for SUR1 by phosphorothioated antisense oligodeoxynucleotide essentially eliminated ca

114 al myocytes with the PKCalpha and PKCepsilon antisense oligodeoxynucleotides for 5 days significantly

115 Lipofection of MNCs with antisense oligodeoxynucleotides for ERK-1/2 resulted in

116 ut not reversed by intrathecal injections of antisense oligodeoxynucleotides for the cytoplasmic poly

117 Antisense oligodeoxynucleotides formulated in cream prep

118 umbar intrathecal administration of specific antisense oligodeoxynucleotides generated against Na(v)1

119 Either D2 or D3 antisense oligodeoxynucleotides greatly attenuated the a

120 Targeting of c-Myb by antisense oligodeoxynucleotides has suggested that myelo

121 circadian pacemaker and VIP antagonists, and antisense oligodeoxynucleotides have been shown to disru

122 oporphyrin (CrMP) or of HO-2 expression with antisense oligodeoxynucleotides (HO-2 AS-ODN).

123 eatment of GN mice with connexin 43-specific antisense oligodeoxynucleotide improved functional and s

124 sents a rational target for modulation using antisense oligodeoxynucleotides in Bcl-2-expressing, EBV

125 d by the D1 antagonist SKF83742 and by a D1A antisense oligodeoxynucleotide, indicating involvement o

126 Treatment with TIN-ag antisense oligodeoxynucleotide induced dysmorphogenesis

127 Treatment with fibrillin-2 antisense oligodeoxynucleotide induced dysmorphogenesis

128 Furthermore, since the above antisense oligodeoxynucleotides inhibit enzyme activatio

129 hypothalamic astrocytes by treatment with an antisense oligodeoxynucleotide inhibited the astrocytic

130 chop in normal murine bone marrow cells with antisense oligodeoxynucleotides inhibited colony-forming

131 Blocking endogenous Per1 with antisense oligodeoxynucleotides inhibited GRP-induced in

132 , the downregulation of E2F4 expression with antisense oligodeoxynucleotides inhibited NGF-induced ne

133 hermore, intrahippocampal injections of RhoA antisense oligodeoxynucleotides inhibited theta burst st

134 We utilized immunoperturbation and antisense oligodeoxynucleotide inhibitory strategies to

135 Delivery of OPN antisense oligodeoxynucleotides into mouse skin wounds b

136 reconsolidation, through infusion of Zif268 antisense oligodeoxynucleotides into the basolateral amy

137 Here, we show that infusion of Zif268 antisense oligodeoxynucleotides into the basolateral amy

138 Finally, infusions of Arc antisense oligodeoxynucleotides into the dorsal hippocam

139 By infusing antisense oligodeoxynucleotides into the hippocampus of

140 In this report, injection of antisense oligodeoxynucleotides into Xenopus laevis oocy

141 Phosphorothioated DNase I antisense oligodeoxynucleotide introduced into cultured

142 etics, and antitumor activity of the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A; IS

143 Cavalpha2delta1 proteins, or Cavalpha2delta1 antisense oligodeoxynucleotides led to a reversal of oro

144 umor cells with appropriate phosphorothioate antisense oligodeoxynucleotides led to specific inhibiti

145 After treatment with CCL1 antisense oligodeoxynucleotides, M2bM disappeared in MLN

146 These studies demonstrate that Bcl-2 antisense oligodeoxynucleotides mediate sequence-depende

147 memory consolidation, as their blockade via antisense oligodeoxynucleotide-mediated knockdown leads

148 levels were reduced experimentally, by using antisense oligodeoxynucleotides, mitotic activity in the

149 EphB4 knockdown using specific siRNA and antisense oligodeoxynucleotides molecules led to a profo

150 hase advances in the rat SCN were blocked by antisense oligodeoxynucleotide (ODN) against Per1 and Ca

151 An antisense oligodeoxynucleotide (ODN) approach was used t

152 We used an antisense oligodeoxynucleotide (ODN) complementary to in

153 ex to AMPA, in the absence or presence of an antisense oligodeoxynucleotide (ODN) directed against Bc

154 Antisense oligodeoxynucleotide (ODN) drugs might be more

155 A c-fos antisense oligodeoxynucleotide (ODN) inhibited AP-1, but

156 of Na(v)1.8 (PN3/SNS) sodium channels by an antisense oligodeoxynucleotide (ODN) on bladder nocicept

157 clear vitamin D receptor (nVDR) knockout via antisense oligodeoxynucleotide (ODN) prevented the inhib

158 and BDNF expression was manipulated using an antisense oligodeoxynucleotide (ODN) strategy.

159 Antisense oligodeoxynucleotide (ODN) to mannose receptor

160 With the use of a phosphorothioated antisense oligodeoxynucleotide (ODN) to p21, which has p

161 An antisense oligodeoxynucleotide (ODN) to the cloned rat K

162 Conversely, embryonic lung culture with an antisense oligodeoxynucleotide (ODN) to the Flk-1 recept

163 In a complementary study, TLR4 antisense oligodeoxynucleotide (ODN) was administered in

164 eriments, intra-LA infusion of an Arc/Arg3.1 antisense oligodeoxynucleotide (ODN) was observed to be

165 se inhibited by blocking PSF with a specific antisense oligodeoxynucleotide (ODN).

166 lved in the increase in conductance by using antisense oligodeoxynucleotides (ODN) derived from the a

167 Pretraining infusions of antisense oligodeoxynucleotides (ODN) directed against C

168 on with reverse complementary, or so called 'antisense', oligodeoxynucleotides (ODN).

169 asis on c-ros and c-ret, was investigated by antisense-oligodeoxynucleotide (ODN) gene-targeting stra

170 Antisense oligodeoxynucleotides (ODNs) and inhibitors of

171 Antisense oligodeoxynucleotides (ODNs) are capable of in

172 The first generation of antisense oligodeoxynucleotides (ODNs) are now undergoin

173 rimary cerebellar cultures were treated with antisense oligodeoxynucleotides (ODNs) complementary to

174 phagocytosis was examined with two forms of antisense oligodeoxynucleotides (ODNs) designed to hybri

175 We used intraventricular infusions of antisense oligodeoxynucleotides (ODNs) directed against

176 ha2C adrenoceptors) were exposed to 5 microM antisense oligodeoxynucleotides (ODNs) for alpha2A and a

177 eption but also for alpha 2 antinociception, antisense oligodeoxynucleotides (ODNs) for the mu-opioid

178 Antisense oligodeoxynucleotides (ODNs) have biological a

179 Specific knockdown of Arc using antisense oligodeoxynucleotides (ODNs) in DH or VH atten

180 Both siRNA and antisense oligodeoxynucleotides (ODNs) inhibit the expre

181 Transient MCAO in rats infused with GLT-1 antisense oligodeoxynucleotides (ODNs) led to increased

182 3-kinase (PI 3-kinase), since inhibitors and antisense oligodeoxynucleotides (ODNs) of Src and PI 3-k

183 Intrathecal administration of antisense oligodeoxynucleotides (ODNs) targeting Nav1.3

184 tubule cells, two strategies were used: (i) antisense oligodeoxynucleotides (ODNs) to selectively in

185 We used chronic in vivo infusion of antisense oligodeoxynucleotides (ODNs) to suppress NMDA

186 human papillomavirus type 16 (HPV-16) E6 and antisense oligodeoxynucleotides (ODNs) were used to supp

187 B4 expression by small interference RNA (and antisense oligodeoxynucleotides (ODNs)) led to dose-depe

188 improve intracellular delivery of synthetic antisense oligodeoxynucleotides (ODNs), thereby enhancin

189 l role of the MocuFH1 gene was studied using antisense oligodeoxynucleotides (ODNs), which transientl

190 both neonatal and adult myocytes; the 15-mer antisense oligodeoxynucleotides of each were used for th

191 Antisense oligodeoxynucleotides offer potential as thera

192 ate intercellular adhesion molecule (ICAM)-1 antisense oligodeoxynucleotide (oligo) IP-9125 blocks th

193 e (PS) groups to natural phosphodiester (PD) antisense oligodeoxynucleotides (oligo) prevents their i

194 Antisense oligodeoxynucleotides (oligos) are widely used

195 used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for th

196 Application of antisense oligodeoxynucleotides or blocking antibody to

197 Inclusion of alphaV-antisense-oligodeoxynucleotide or -antibody in metanephr

198 TSP4 blockade by intrathecal antibodies, antisense oligodeoxynucleotides, or inactivation of the

199 down technologies, such as RNA interference, antisense oligodeoxynucleotides, or ribozymes, are limit

200 ignature induced by the exogenously supplied antisense oligodeoxynucleotide overlaps strikingly with

201 ng explants, while TGF-beta type II receptor antisense oligodeoxynucleotides prevented the downregula

202 Attenuating expression of Na(V)1.8 with antisense oligodeoxynucleotides prevented the redistribu

203 in in the dorsal root ganglion with specific antisense oligodeoxynucleotides prevents hyperalgesia an

204 Antisense oligodeoxynucleotides produced a significant d

205 Conversely, treatment with TNFR2 antisense oligodeoxynucleotides reduced liver metastasis

206 Downregulation of Kv1.5 protein by antisense oligodeoxynucleotides reduces astrocyte prolif

207 hibitors Z-VAD FMK and Z-DEVD FMK, and c-Myc antisense oligodeoxynucleotide, respectively.

208 C3T3-E1 osteoblastic cells treated with P2Y2 antisense oligodeoxynucleotides responded to fluid flow

209 In addition, ICP4 and pp38 antisense oligodeoxynucleotides resulted in 77- and 100-

210 Phenotypically, Smad antisense oligodeoxynucleotides resulted in a concentrat

211 Treatment of cells with beta-catenin antisense oligodeoxynucleotides resulted in a decrease i

212 nt with either megalin antibodies or megalin antisense oligodeoxynucleotides resulted in inhibition o

213 ion of xGu in Xenopus laevis oocyte using an antisense oligodeoxynucleotide results in the depletion

214 Inhibition experiments with antisense oligodeoxynucleotides revealed that Matrigel i

215 AT1R mRNA (100 microg/rat, n=9) or scrambled antisense oligodeoxynucleotides (Scr-ODNs, 100 microg/ra

216 protein using EphB4 short interfering RNA or antisense oligodeoxynucleotide significantly inhibits ce

217 on either by high glucose conditions or with antisense oligodeoxynucleotides significantly lowers pro

218 l lines of vascular smooth muscle cells with antisense oligodeoxynucleotide specific to p21(Waf1/Cip1

219 hic receptor binding revealed that D2 and D3 antisense oligodeoxynucleotides specifically and signifi

220 y formation was suppressed by treatment with antisense oligodeoxynucleotides specifically downregulat

221 Our previous work with antisense oligodeoxynucleotides suggested that the proto

222 Depletion of MEKK1, -2, or -4 by antisense oligodeoxynucleotides suppressed signaling fro

223 An mRNA transcript contains many potential antisense oligodeoxynucleotide target sites.

224 Overexpression of Bcl-x(L) or treatment with antisense oligodeoxynucleotides targeted against Bax sig

225 re we test the potential of phosphorothioate antisense oligodeoxynucleotides targeted against human C

226 ulating cell cycle progression, we developed antisense oligodeoxynucleotides targeted against PP5 (e.

227 Moreover, multiple antisense oligodeoxynucleotides targeted to different re

228 Intracerebral injection of antisense oligodeoxynucleotides targeted to GluR2 mRNA i

229 We have used antisense oligodeoxynucleotides targeted to LMP-1 as a s

230 ODNBase is a database of antisense oligodeoxynucleotides targeted to mammalian mR

231 MI-8392 cells with an 18-bp phosphorothioate antisense oligodeoxynucleotide, targeted against the tra

232 Antisense oligodeoxynucleotide targeting EphB4 in vivo s

233 onstrate the in vivo antitumor effects of an antisense oligodeoxynucleotide targeting PKC-alpha and s

234 istration of an aerosolized phosphorothioate antisense oligodeoxynucleotide targeting the adenosine A

235 Phosphorothioated derivatives of antisense oligodeoxynucleotides targeting a conserved se

236 dothelial NO synthase, and 3) application of antisense oligodeoxynucleotides targeting endothelial NO

237 Intrathecal antisense oligodeoxynucleotides targeting Na(v)1.3 decre

238 We then administered antisense oligodeoxynucleotides targeting Notch3 or scra

239 the synthesis of PLP in glial cultures with antisense oligodeoxynucleotides that targeted the PLP in

240 rget mRNA is cleaved, upon treatment with an antisense oligodeoxynucleotide, the 3' cleavage product

241 ls of PAM in HeLa cells were decreased using antisense oligodeoxynucleotides, the basal cAMP content

242 However, administering antisense oligodeoxynucleotide to attenuate ET(A) recept

243 phy (LVH), we inhibited EGFR with a specific antisense oligodeoxynucleotide to attenuate the Ang II-i

244 Both FR901228 and antisense oligodeoxynucleotide to c-myc had similar effe

245 e effect of intracerebellar microinfusion of antisense oligodeoxynucleotide to Delta(9)-tetrahydrocan

246 The antisense oligodeoxynucleotide to EGFR (EGFR-AS) was des

247 in bovine aortic endothelial cells using an antisense oligodeoxynucleotide to G6PD or increased G6PD

248 ter intrathecal injection of a gene-specific antisense oligodeoxynucleotide to knock down the express

249 K562 cells treated for several days with an antisense oligodeoxynucleotide to the initiation codon r

250 cked by PD098059 as well as by both KN93 and antisense oligodeoxynucleotides to CaMKII.

251 solated cerebral arteries treated with TRPM4 antisense oligodeoxynucleotides to downregulate channel

252 Antisense oligodeoxynucleotides to flk-1, but not flt-1,

253 f MOR-1 gene expression by administration of antisense oligodeoxynucleotides to hippocampal slices in

254 Treating bone marrow cells with antisense oligodeoxynucleotides to HOX A5 resulted in in

255 We used intrahippocampal infusions of antisense oligodeoxynucleotides to inhibit Arc protein e

256 by chimeric methylphosphonate/phosphodiester antisense oligodeoxynucleotides to just 5% of control le

257 tion of the myeloid cells, and expression of antisense oligodeoxynucleotides to p107 mRNA blocked TGF

258 Antisense oligodeoxynucleotides to PKC-alpha and p47phox

259 In contrast, antisense oligodeoxynucleotides to PKC-alpha, -beta, -ga

260 We used antisense oligodeoxynucleotides to produce intact swine

261 We are investigating the use of antisense oligodeoxynucleotides to selectively suppress

262 s, Western blotting, and chemical inhibitors/antisense oligodeoxynucleotides to signaling intermediat

263 HCAECs were incubated in the presence of antisense oligodeoxynucleotides to the 5'-coding sequenc

264 Ba/F3-EpoR were then treated with antisense oligodeoxynucleotides to the murine beta.

265 Antisense oligodeoxynucleotides to TRPC6 decreased TRPC6

266 Spinal administration of antisense oligodeoxynucleotides to TRPV4, which reduced

267 Treatment of AV canal explants with either antisense oligodeoxynucleotides toward Slug or anti-TGFb

268 region binding protein(s) by insulin in the antisense oligodeoxynucleotide-treated explants.

269 Antisense oligodeoxynucleotide treatment inhibited Manx

270 per antisense oligodeoxynucleotide treatment of pharate larv

271 ta type II receptor immunoperturbation or of antisense oligodeoxynucleotide treatment on lung branchi

272 Furthermore, megalin antisense oligodeoxynucleotide treatment resulted in red

273 Through the usage of decorin-specific antisense oligodeoxynucleotide treatment, we demonstrate

274 stimulatory effect on lung branching of Smad antisense oligodeoxynucleotide treatment.

275 MDAR subunits NR1, NR2B, NR2D, and NR3A with antisense-oligodeoxynucleotide treatment in the DRG.

276 atenin levels were treated with beta-catenin antisense oligodeoxynucleotides, VEGF-A expression was r

277 By using a mouse model, we deliver OPN antisense oligodeoxynucleotides via Pluronic gel to the

278 rvival, since transfection of Mcl-1-specific antisense oligodeoxynucleotides was sufficient to promot

279 Furthermore, using antisense oligodeoxynucleotides, we show that Sry downre

280 present study, using specific antibodies and antisense oligodeoxynucleotides, we show that this proli

281 Antisense oligodeoxynucleotides were designed to attenua

282 Antisense oligodeoxynucleotides were used to determine w

283 lated by up to 53% in culture with 40 microM antisense oligodeoxynucleotide, whereas both scrambled a

284 ptake were inhibited by exogenous LRP or LRP antisense oligodeoxynucleotides, whereas they were incre

285 Treatment with calbindin-D28K antisense oligodeoxynucleotides, which significantly dec

286 GED-0301 is an antisense oligodeoxynucleotide with a sequence complemen

287 support the investigation of combinations of antisense oligodeoxynucleotides with cytotoxic chemother

288 acerebroventricular infusion (3-4 d) of G(z) antisense oligodeoxynucleotides, with different sequence